Catheter-Related Bloodstream Infections Review

Abebe, Abebe; Tener, Mitch; Waller, Stephen C.; Atrouni, Wissam El

doi:10.1016/j.ehmc.2013.08.002

Cited by 6 publications

(6 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further examine the potential for using PU+auranofin coated catheters clinically, coated catheter segments formulated using 3 and 10 mg/mL auranofin were exposed to MRSA and then examined for biofilm formation over 48 h. PU+vancomycin, auranofin only (lacking PU, formulated with 3 mg/mL auranofin), and PU only coatings were also examined along with uncoated catheters. Vancomycin, a potent glycopeptide antibiotic highly effective against MRSA (Abebe et al, 2014), was loaded onto the catheters as a control to test its antibiofilm efficacy in comparison to auranofin coatings. Biofilm accumulation on catheter segments was visualized using an IVIS imaging system as seen in Figure 7A with luminescence indicating the presence of bacteria.…”

Section: Resultsmentioning

confidence: 99%

“…With the use of these intravascular devices comes a risk of catheter-related bloodstream infections (CRBSIs). Over 250,000 CRBSIs are diagnosed annually in the U.S. (Maki et al, 2006), making CRBSIs the most prevalent source of nosocomial bacteremia (Abebe et al, 2014). These infections can prolong hospital stays by ~10–20 days and increase the cost of care from $4,000 to $56,000 per patient; more importantly, CRBSIs are associated with mortality rates of 12–25% (Maki et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

“…CRBSIs are predominantly caused by Gram-positive bacteria including species of Staphylococcus aureus (Abebe et al, 2014). Intravascular catheters can become infected by microorganisms in several ways: the catheter lumen can be contaminated prior to use, the catheter tip and cutaneous tract can be contaminated by the skin microbiome during insertion, contaminated infusate can deliver bacteria, and inserted materials can be exposed to microbes due to an existing systemic infection (Pugach et al, 1999; Abebe et al, 2014). Once bacteria are introduced to the catheter material, they can adhere and begin the process of forming a biofilm, playing a significant role in CRBSI pathogenesis (Donlan, 2002; Raad et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings

Liu

Shukla

Vera‐González

et al. 2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Intravascular catheter related bloodstream infections (CRBSIs) are a leading cause of hospital-acquired infections worldwide, resulting not only in the burden of cost and morbidity for patients but also in the over-consumption of medical resources for hospitals and health care organizations. In this study, a novel auranofin releasing antibacterial and antibiofilm polyurethane (PU) catheter coating was developed and investigated for future use in preventing CRBSIs. Auranofin is an antirheumatic drug with recently identified antimicrobial properties. The drug carrier, PU, acts as a barrier surrounding the antibacterial agent, auranofin, to extend the drug release profile and improve its long-term antibacterial and antibiofilm efficacy and potentially the length of catheter implantation within a patient. The PU+auranofin coatings developed here were found to be highly stretchable (exhibiting ~500% percent elongation), which is important for the compliance of the material on a flexible catheter. PU+auranofin coated catheters were able to inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA) for 8 to 26 days depending on the specific drug concentration utilized during the dip coating process. The PU+auranofin coated catheters were also able to completely inhibit MRSA biofilm formation in vitro , an effect that was not observed with auranofin or PU alone. Lastly, these coatings were found to be hemocompatible with human erythrocytes and maintain liver cell viability.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings

Liu

Shukla

Vera‐González

et al. 2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Several case studies [15][16][17] have been reported over the past few years, and have shown a decrease in catheter dislodgment/malposition rates, even during the anxiety provoking dressing change process. 18 These same studies noted that CRBSI Outcomes based on securement products vary, which is to be expected. Although suture provides immediate securement it does not prevent CVC movement over time, it is associated with safety issues for the patient, and it may hinder skin disinfection associated with dressing changes.…”

Section: Product Issuesmentioning

confidence: 86%

Central Venous Catheter Securement: Using the Healthcare and Technology Synergy Model to Take a Closer Look

Macklin

Blackburn

2015

Journal of the Association for Vascular Access

View full text Add to dashboard Cite

Proper securement provides a safe vascular access device environment for both patients and health care providers. Successful securement protects central venous catheters from several sources of failure until the end of therapy by preventing central venous catheter movement during all phases of care. Movement causes vein trauma, bacterial migration, distal tip location variation, loss of dressing integrity, and even total dislodgement. Any of these events can have serious consequences, including catheter-related bloodstream infection, thrombosis, delay of treatment, catheter replacement, and potential hemorrhage, all of which can be life-threatening events, and increase costs. We review patient issues, practice issues, and the types of securement currently used in clinical settings.

show abstract

“…A review of several case studies has been published indicating a dramatic decrease in catheter dislodgement/malposition rates. 25 Just as with the previously mentioned devices, securement devices must be evaluated for the pros and cons they bring to an individual patient situation.…”

Section: Securement Devicesmentioning

confidence: 99%

Catheter-Related Bloodstream Infections (CR-BSI) in Geriatric Patients in Intensive Care Units

Chernecky

Macklin

Blackburn³

2015

Critical Care Nursing Quarterly

View full text Add to dashboard Cite

Catheter-related bloodstream infections (CR-BSIs) are bloodstream infections that, through specific laboratory testing, identify the intravascular catheter as the source of the bloodstream infection. By 2015, the rate of elderly patients 80 years of age and older admitted to the intensive care unit (ICU) will represent 1 in 4 admissions. Approximately 80 000 CR-BSIs occur in ICUs annually, potentially resulting in as many as 56 000 CR-BSIs occurring in the geriatric ICU patient, with 20% of these cases resulting in death. To minimize the occurrence of CR-BSIs in these patients, specific knowledge about the geriatric patient will have to be factored into the ICU health care professional's practice, including the development of a vascular access plan, which includes selection of the correct device and proper insertion of that device along with an evidence-based care and maintenance program. Intensive care unit health care professionals may be at a loss when it comes to navigating the vast array of vascular access medical devices available today. The Healthcare and Technology Synergy framework can assist the ICU health care professional to logically review each vascular access device and select those devices that best meet patient needs.

show abstract

Catheter-Related Bloodstream Infections Review

Cited by 6 publications

References 71 publications

Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings

Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings

Central Venous Catheter Securement: Using the Healthcare and Technology Synergy Model to Take a Closer Look

Catheter-Related Bloodstream Infections (CR-BSI) in Geriatric Patients in Intensive Care Units

Contact Info

Product

Resources

About